Outcome of the Board Meeting held on May 05, 2026.
EMCURE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Emcure Pharmaceuticals reported strong FY26 results with consolidated revenue of Rs 92,035.40 million (up 16.6% from Rs 78,959.97 million) and consolidated profit of Rs 9,412.69 million (up 33% from Rs 7,074.67 million). EPS grew to Rs 48.77 from Rs 36.43. The Board recommended a final dividend of Rs 3.60 per share (36%). Exceptional items included one-time provisions of Rs 313.49 million for Canada Drug Pricing legal matters and New Labour Codes employee benefits. Key corporate actions include acquiring remaining 49% stake in Zuventus Healthcare making it a wholly-owned subsidiary, and Mantra Pharma Inc. (subsidiary) acquiring Cutimed Inc. for CAD 5.05 million to strengthen Canadian dermatology portfolio. Dr. Mukund Gurjar was re-appointed as Whole-time Director for 1 year and Mr. Satish Mehta as Managing Director for 5 years. Auditors issued unmodified opinion on both standalone and consolidated financials.
Strong profit growth of 33% YoY and 16.6% revenue growth indicate solid operational performance. Dividend declaration signals confidence in cash flows. Acquisitions and subsidiary restructuring may create long-term value.